Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 6/2011

01.12.2011 | Original Article

Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation

verfasst von: Cristina P. R. Xavier, Cristovao F. Lima, Mikkel Rohde, Cristina Pereira-Wilson

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Colorectal tumors (CRC) with microsatellite instability (MSI) show resistance to chemotherapy with 5-fluorouracil (5-FU), the most widely used pharmacological drug for CRC treatment. The aims of this study were to test the ability of quercetin (Q) and luteolin (L) to increase the sensitivity of MSI CRC cells to 5-FU and characterize the dependence of the effects on cells’ p53 status.

Methods

Two MSI human CRC-derived cell lines were used: CO115 wild type (wt) for p53 and HCT15 that harbors a p53 mutation. Apoptosis induction in these cells by 5-FU, Q and L alone, and in combinations was evaluated by TUNEL and western blot. The dependence of the effects on p53 was confirmed by small interference RNA (siRNA) in CO115 cells and in MSI HCT116 wt and p53 knockout cells.

Results

CO115 p53-wt cells are more sensitive to 5-FU than the p53-mutated HCT15. The combination treatment of 5-FU with L and Q increased apoptosis with a significant effect for Q in CO115. Both flavonoids increased p53 expression in both cell lines, an effect particularly remarkable for Q. The significant apoptotic enhancement in CO115 incubated with Q plus 5-FU involved the activation of the apoptotic mitochondrial pathway. Importantly, knockdown of p53 by siRNA in CO115 cells and p53 knockout in HCT116 cells totally abrogated apoptosis induction, demonstrating the dependence of the effect on p53 modulation by Q.

Conclusion

This study suggests the potential applicability of these phytochemicals for enhancement 5-FU efficiency in MSI CRC therapy, especially Q in p53 wt tumors.
Literatur
1.
Zurück zum Zitat Rupnarain C, Dlamini Z, Naicker S, Bhoola K (2004) Colon cancer: genomics and apoptotic events. Biol Chem 385:449–464PubMedCrossRef Rupnarain C, Dlamini Z, Naicker S, Bhoola K (2004) Colon cancer: genomics and apoptotic events. Biol Chem 385:449–464PubMedCrossRef
2.
Zurück zum Zitat Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247–257PubMedCrossRef Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247–257PubMedCrossRef
3.
Zurück zum Zitat Bhushan S, McLeod H, Walko CM (2009) Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. Clin Colorectal Cancer 8:15–21PubMedCrossRef Bhushan S, McLeod H, Walko CM (2009) Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. Clin Colorectal Cancer 8:15–21PubMedCrossRef
4.
Zurück zum Zitat Mader RM, Muller M, Steger GG (1998) Resistance to 5-fluorouracil. Gen Pharmacol 31:661–666PubMedCrossRef Mader RM, Muller M, Steger GG (1998) Resistance to 5-fluorouracil. Gen Pharmacol 31:661–666PubMedCrossRef
5.
Zurück zum Zitat Huerta S, Goulet EJ, Livingston EH (2006) Colon cancer and apoptosis. Am J Surg 191:517–526PubMedCrossRef Huerta S, Goulet EJ, Livingston EH (2006) Colon cancer and apoptosis. Am J Surg 191:517–526PubMedCrossRef
6.
Zurück zum Zitat Davies JM, Goldberg RM (2008) First-line therapeutic strategies in metastatic colorectal cancer. Oncology (Williston Park) 22:1470–1479 Davies JM, Goldberg RM (2008) First-line therapeutic strategies in metastatic colorectal cancer. Oncology (Williston Park) 22:1470–1479
7.
Zurück zum Zitat Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Pinol V, Xicola RM, Bujanda L, Rene JM, Clofent J, Bessa X, Morillas JD, Nicolas-Perez D, Paya A, Alenda C (2006) Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55:848–855PubMedCrossRef Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Pinol V, Xicola RM, Bujanda L, Rene JM, Clofent J, Bessa X, Morillas JD, Nicolas-Perez D, Paya A, Alenda C (2006) Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55:848–855PubMedCrossRef
8.
Zurück zum Zitat Warusavitarne J, Schnitzler M (2007) The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis 22:739–748PubMedCrossRef Warusavitarne J, Schnitzler M (2007) The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis 22:739–748PubMedCrossRef
9.
Zurück zum Zitat Soreide K, Janssen EA, Soiland H, Korner H, Baak JP (2006) Microsatellite instability in colorectal cancer. Br J Surg 93:395–406PubMedCrossRef Soreide K, Janssen EA, Soiland H, Korner H, Baak JP (2006) Microsatellite instability in colorectal cancer. Br J Surg 93:395–406PubMedCrossRef
10.
Zurück zum Zitat Sinicrope FA, Sargent DJ (2009) Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 21:369–373PubMedCrossRef Sinicrope FA, Sargent DJ (2009) Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 21:369–373PubMedCrossRef
11.
Zurück zum Zitat Seruca R, Velho S, Oliveira C, Leite M, Matos P, Jordan P (2009) Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors. Expert Rev Gastroenterol Hepatol 3:5–9PubMedCrossRef Seruca R, Velho S, Oliveira C, Leite M, Matos P, Jordan P (2009) Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors. Expert Rev Gastroenterol Hepatol 3:5–9PubMedCrossRef
12.
Zurück zum Zitat Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC (1996) p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 69:190–192PubMedCrossRef Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC (1996) p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 69:190–192PubMedCrossRef
13.
Zurück zum Zitat Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, Lacorte JM, Staedel C, Lesuffleur T (2002) Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 98:498–504PubMedCrossRef Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, Lacorte JM, Staedel C, Lesuffleur T (2002) Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 98:498–504PubMedCrossRef
14.
Zurück zum Zitat Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263–269PubMedCrossRef Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263–269PubMedCrossRef
15.
Zurück zum Zitat Adamsen BL, Kravik KL, Clausen OP, De Angelis PM (2007) Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int J Oncol 31:1491–1500PubMed Adamsen BL, Kravik KL, Clausen OP, De Angelis PM (2007) Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int J Oncol 31:1491–1500PubMed
16.
Zurück zum Zitat Mori S, Ogata Y, Shirouzu K (2004) Biological features of sporadic colorectal carcinoma with high-frequency microsatellite instability: special reference to tumor proliferation and apoptosis. Int J Clin Oncol 9:322–329PubMedCrossRef Mori S, Ogata Y, Shirouzu K (2004) Biological features of sporadic colorectal carcinoma with high-frequency microsatellite instability: special reference to tumor proliferation and apoptosis. Int J Clin Oncol 9:322–329PubMedCrossRef
17.
Zurück zum Zitat Hector S, Prehn JH (2009) Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: A review. Biochim Biophys Acta 1795:117–129PubMed Hector S, Prehn JH (2009) Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: A review. Biochim Biophys Acta 1795:117–129PubMed
18.
Zurück zum Zitat Aggarwal BB, Shishodia S (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71:1397–1421PubMedCrossRef Aggarwal BB, Shishodia S (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71:1397–1421PubMedCrossRef
19.
Zurück zum Zitat Ramos S (2008) Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol Nutr Food Res 52:507–526PubMedCrossRef Ramos S (2008) Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol Nutr Food Res 52:507–526PubMedCrossRef
20.
Zurück zum Zitat Subapriya Rajamanickam RA (2008) Natural products and colon cancer: current status and future prospects. Drug Dev Res 69:460–471PubMedCrossRef Subapriya Rajamanickam RA (2008) Natural products and colon cancer: current status and future prospects. Drug Dev Res 69:460–471PubMedCrossRef
21.
Zurück zum Zitat Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9:537–549PubMedCrossRef Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9:537–549PubMedCrossRef
22.
Zurück zum Zitat Liu J, Lin A (2005) Role of JNK activation in apoptosis: a double-edged sword. Cell Res 15:36–42PubMedCrossRef Liu J, Lin A (2005) Role of JNK activation in apoptosis: a double-edged sword. Cell Res 15:36–42PubMedCrossRef
23.
Zurück zum Zitat Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA (2009) p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 15:369–379PubMedCrossRef Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA (2009) p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 15:369–379PubMedCrossRef
24.
Zurück zum Zitat Xavier CP, Lima CF, Preto A, Seruca R, Fernandes-Ferreira M, Pereira-Wilson C (2009) Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells. Cancer Lett 281:162–170PubMedCrossRef Xavier CP, Lima CF, Preto A, Seruca R, Fernandes-Ferreira M, Pereira-Wilson C (2009) Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells. Cancer Lett 281:162–170PubMedCrossRef
25.
Zurück zum Zitat Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, Cottu P, Hamelin R (2001) Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene 20:5025–5032PubMedCrossRef Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, Cottu P, Hamelin R (2001) Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene 20:5025–5032PubMedCrossRef
26.
Zurück zum Zitat Barbour KW, Berger FG (2008) Cell death in response to antimetabolites directed at thymidylate synthase. Cancer Chemother Pharmacol 61:189–201PubMedCrossRef Barbour KW, Berger FG (2008) Cell death in response to antimetabolites directed at thymidylate synthase. Cancer Chemother Pharmacol 61:189–201PubMedCrossRef
27.
Zurück zum Zitat Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497–1501PubMedCrossRef Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497–1501PubMedCrossRef
28.
Zurück zum Zitat Preto A, Figueiredo J, Velho S, Ribeiro A, Soares P, Oliveira C, Seruca R (2008) BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. J Pathol 214:320–327PubMedCrossRef Preto A, Figueiredo J, Velho S, Ribeiro A, Soares P, Oliveira C, Seruca R (2008) BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. J Pathol 214:320–327PubMedCrossRef
29.
Zurück zum Zitat Itoh N, Semba S, Ito M, Takeda H, Kawata S, Yamakawa M (2002) Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 94:3127–3134PubMedCrossRef Itoh N, Semba S, Ito M, Takeda H, Kawata S, Yamakawa M (2002) Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 94:3127–3134PubMedCrossRef
30.
Zurück zum Zitat Osaki M, Oshimura M, Ito H (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9:667–676PubMedCrossRef Osaki M, Oshimura M, Ito H (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9:667–676PubMedCrossRef
31.
Zurück zum Zitat Rychahou PG, Jackson LN, Silva SR, Rajaraman S, Evers BM (2006) Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg 243:833–842 discussion 843–844PubMedCrossRef Rychahou PG, Jackson LN, Silva SR, Rajaraman S, Evers BM (2006) Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg 243:833–842 discussion 843–844PubMedCrossRef
32.
Zurück zum Zitat Thompson N, Lyons J (2005) Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5:350–356PubMedCrossRef Thompson N, Lyons J (2005) Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5:350–356PubMedCrossRef
33.
Zurück zum Zitat McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D’Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249–279PubMedCrossRef McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D’Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249–279PubMedCrossRef
34.
Zurück zum Zitat Tang XY, Zhu YQ, Tao WH, Wei B, Lin XL (2007) Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. Postgrad Med J 83:338–343PubMedCrossRef Tang XY, Zhu YQ, Tao WH, Wei B, Lin XL (2007) Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. Postgrad Med J 83:338–343PubMedCrossRef
35.
Zurück zum Zitat Zhang YQ, Tang XQ, Sun L, Dong L, Qin Y, Liu HQ, Xia H, Cao JG (2007) Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma. World J Gastroenterol 13:1534–1540PubMedCrossRef Zhang YQ, Tang XQ, Sun L, Dong L, Qin Y, Liu HQ, Xia H, Cao JG (2007) Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma. World J Gastroenterol 13:1534–1540PubMedCrossRef
36.
Zurück zum Zitat Wang CZ, Luo X, Zhang B, Song WX, Ni M, Mehendale S, Xie JT, Aung HH, He TC, Yuan CS (2007) Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells. Cancer Chemother Pharmacol 60:69–79PubMedCrossRef Wang CZ, Luo X, Zhang B, Song WX, Ni M, Mehendale S, Xie JT, Aung HH, He TC, Yuan CS (2007) Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells. Cancer Chemother Pharmacol 60:69–79PubMedCrossRef
37.
Zurück zum Zitat Shi R, Huang Q, Zhu X, Ong YB, Zhao B, Lu J, Ong CN, Shen HM (2007) Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization. Mol Cancer Ther 6:1338–1347PubMedCrossRef Shi R, Huang Q, Zhu X, Ong YB, Zhao B, Lu J, Ong CN, Shen HM (2007) Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization. Mol Cancer Ther 6:1338–1347PubMedCrossRef
38.
Zurück zum Zitat Hou Q (2008) Effect of staurosporine induced apoptosis of MCF7/GFP-Bax stable cell line on Bax translocation from cytosol into mitochondria. Yao Xue Xue Bao 43:378–382PubMed Hou Q (2008) Effect of staurosporine induced apoptosis of MCF7/GFP-Bax stable cell line on Bax translocation from cytosol into mitochondria. Yao Xue Xue Bao 43:378–382PubMed
Metadaten
Titel
Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation
verfasst von
Cristina P. R. Xavier
Cristovao F. Lima
Mikkel Rohde
Cristina Pereira-Wilson
Publikationsdatum
01.12.2011
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 6/2011
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-011-1641-9

Weitere Artikel der Ausgabe 6/2011

Cancer Chemotherapy and Pharmacology 6/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.